761423-87-4
761423-87-4 structure
- Name: Ipragliflozin
- Chemical Name: (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
- CAS Number: 761423-87-4
- Molecular Formula: C21H21FO5S
- Molecular Weight: 404.452
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel SGLT
- Create Date: 2018-02-14 08:00:00
- Modify Date: 2025-08-20 09:49:03
-
Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.IC50 value: 2.8 nM [1][2]Target: SGLT2in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases [3].in vivo: Ipragliflozin showed good pharmacokinetic properties following oral dosing, and dose-dependently increased urinary glucose excretion, which lasted for over 12 h in normal mice [3]. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h [4]. Single administration of ipragliflozin dose-dependently increased urinary glucose excretion, reduced blood glucose and plasma insulin levels, and improved glucose intolerance [5].
| Name | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
|---|---|
| Synonyms |
D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-
ASP1941 UNII-3N2N8OOR7X ASP 1941 (1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol Suglat Ipragliflozin |
| Description | Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.IC50 value: 2.8 nM [1][2]Target: SGLT2in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases [3].in vivo: Ipragliflozin showed good pharmacokinetic properties following oral dosing, and dose-dependently increased urinary glucose excretion, which lasted for over 12 h in normal mice [3]. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h [4]. Single administration of ipragliflozin dose-dependently increased urinary glucose excretion, reduced blood glucose and plasma insulin levels, and improved glucose intolerance [5]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 628.8±55.0 °C at 760 mmHg |
| Molecular Formula | C21H21FO5S |
| Molecular Weight | 404.452 |
| Flash Point | 334.1±31.5 °C |
| Exact Mass | 404.109375 |
| PSA | 118.39000 |
| LogP | 5.59 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.684 |
| Storage condition | -20℃ |
|
~88%
761423-87-4 |
| Literature: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 13 ; |
|
~97%
761423-87-4 |
| Literature: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 15 ; |
|
~%
761423-87-4 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279 |
|
~%
761423-87-4 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279 |
|
~%
761423-87-4 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279 |
|
~%
761423-87-4 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279 |
| Precursor 5 | |
|---|---|
| DownStream 0 | |